HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
28 hedge funds and large institutions have $5.13M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
400% more call options, than puts
Call options by funds: $5K | Put options by funds: $1K
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
24% less capital invested
Capital invested by funds: $6.79M → $5.13M (-$1.66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
+$700K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$598K |
| 3 |
Renaissance Technologies
New York
|
+$476K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$256K |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$183K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$159K |
| 3 |
Jane Street
New York
|
-$27K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$27K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
27
UBS Group
Zurich,
Switzerland
| – | -$27K | -213 | Closed |
|
|
28
Jane Street
New York
| – | -$27K | -210 | Closed |
|
|
ARTA
29
A.R.T. Advisors
New York
| – | -$15K | -116 | Closed |
|
30
Squarepoint
New York
| – | -$9K | -70 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5.89K | -66 | Closed |
|
32
Simplex Trading
Chicago,
Illinois
| – | -$268 | -3 | Closed |
|
33
Osaic Holdings
Scottsdale,
Arizona
| – | -$89 | -1 | -25% |
|
HTGM Hedge Fund Activity: Q3 2020 in Review
28 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2020, worth a combined $5.13M — down 24% from $6.79M a quarter earlier.
Fund positioning in HTGM was balanced in Q3 2020: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 4 trimmed.
The largest buyer was Cowen Prime Advisors, opening a new position worth an estimated $700K. The largest seller was BlackRock, cutting an estimated $183K.
- 28 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $5.13M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2020, down 24% quarter-over-quarter.
- 6 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2020 and 6 closed out, a net change of 0 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2020 was Cowen Prime Advisors, an estimated $700K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2020 was BlackRock, an estimated $183K sold.
Based on aggregated 13F filings for Q3 2020.